Humana Biotargets of Cancer in Current Clinical Practice (Current Clinical Pathology)

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed. Review From the reviews: “In this book on clinically significant biotargets in cancer research, every organ system is thoroughly represented with adequate overviews and precise details of the biotargets. … the book is intended specifically for clinicians in the field, including medical students, residents, pathologists, and oncologists. … This is a well-written book that attempts to provide a wide spectrum of current scientific information about the clinical management of oncologic patients based on molecular aspects. … this book achieves its objectives while remaining easy to read.” (Natalie Webster, Doody’s Review Service, October, 2012) From the Back Cover Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed. About the Author Mauro Bologna, MD University of L’Aquila, L’Aquila, Italy